According to FutureWise analysis, the market for meningococcal vaccine in 2026 is US$ 5.14 billion, and is expected to reach US$ 10.86 billion by 2036 at a CAGR of 7.77%. The growth is fueled by expanding immunization programs, greater awareness of meningococcal disease prevention, and increased vaccine uptake among infants, adolescents, and high-risk groups. Advances in conjugate and recombinant vaccine technologies are enhancing coverage against various serogroups, while strong government support and global public health initiatives are driving market expansion globally.
Neisseria meningitidis is a bacterium responsible for meningococcal disease, which is a significant cause of bacterial meningitis among children aged 2 to 18 in the United States. Meningococcal disease manifests primarily as meningitis, a serious and potentially fatal inflammation of the membranes surrounding the brain and spinal cord, or as a severe blood infection. Complications from this disease can include limb amputation, hearing loss, neurological issues, intellectual disabilities, convulsions, and strokes. Vaccination plays a crucial role in preventing meningococcal disease.
The disease is transmitted through contact with respiratory secretions, such as saliva. Common ways the bacteria can spread include kissing, sharing eating utensils or drinks, and close physical interactions, such as living together. Vaccination is one of the most effective strategies to prevent meningococcal disease and protect against conditions caused by N. meningitidis, including meningitis, meningococcemia, and septicemia. Among the known serogroups, A, B, C, Y, and W-135 are the most frequently associated with infections. The increasing incidence of meningococcal meningitis represents a significant public health concern. Despite the availability of various treatments for meningococcal infections globally, the disease continues to result in numerous fatalities each year.
FutureWise Market Research has published a report that provides an insightful analysis of Meningococcal Vaccine Market trends that are affecting the overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=10349&type=requestsample
Meningococcal Vaccine Market Segmentation:
By Product
- Polysaccharide Vaccine
- Conjugate Vaccine
- Serogroup B Vaccine
By Age Group
- Infants
- Children
- Adolescents and Young Adults
- Adults
By Distribution Channel
- Institutional Sales
- Hospitals
- Community Clinics
- Public Health Agencies
- Retail Sales
- Retail Pharmacy
- Mail Order Pharmacy
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Meningococcal Vaccine Market:
- Sanofi Pasteur Inc.
- GlaxoSmithKline
- Wyeth Pharmaceuticals
- Biomed Pvt. Ltd.
- JN-International Medical Corporation
- Novartis International AG
- Pfizer, Inc.
- Serum Institute of India Ltd.
- Bio-Manguinhos
- Chongqing Zhifei Biological Products Co., Ltd.
- Hualan Biological Engineering Inc.
- Incepta Pharmaceuticals Ltd.
- Walvax Biotechnology Co.
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10349&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Meningococcal Vaccine Market By Product, By Age Group, By Distribution Channel and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: [email protected]
